Addex Pharmaceuticals wins EuropaBio's Most Innovative European ...

denunequaledBiotechnology

Dec 1, 2012 (4 years and 8 months ago)

238 views

PRESS RELEASE
Addex Pharmaceuticals

wins EuropaBio’s Most Innovative European Biotech SME


Award, 2010

Chris Maggos from Addex Pharmaceuticals accepts the prize
together with Nathalie Moll, EuropaBio Secretary General,
Paola Testori Coggi, Director General DG Health and Consumer Policy and
Tom Saylor, Chair of EuropaBio’s SME Platform.
Brussels
, 10 December 2010
Yesterday
, at EuropaBio’s event on Innovation in Biotechnology,
Addex Pharmaceuticals
was

revealed as the winner of EuropaBio’s Most Innovative European Biotech SME Award before an

audience of EU regulators, CEOs, VCs, stakeholders, industry representatives and journalists.
Addex
triumphed as winners over stiff competition from
31 other biotech companies

demonstrating cutting edge innovation in biotechnology from across the healthcare, agricultural

and industrial sectors.
The
Geneva-based company, which was founded in 2002, was selected as the over all winner by

a high-level judging panel from a final shortlist of five companies which also included
AMSilk
,

KeyGene
,
Prosensa
and
TiGenix
.
Addex Pharmaceuticals were honoured for their
discoveries and developments in the field of

allosteric modulators for human health focused on validated therapeutic targets for diseases of

the central nervous system, metabolic disorders and inflammation.
Commenting on the significance of Addex’s work,
EuropaBio Chairman, Andrea Rappagliosi

said: “Addex showcases the critical role of European SMEs as a booster of knowledge and

understanding of the diseases that are still a major unmet medical need in Europe.
Addex has

pioneered an extremely innovative solution to address important therapeutic areas such as

Parkinson’s disease, schizophrenia, Alzheimer’s disease, endometriosis and benign prostatic

hyperplasia. I would like to congratulate all five finalists. Choosing a winner was a tough task. ”
The company has demonstrated the potential of the technology by advancing
products to Phase

II clinical testing and partnering with two major pharmaceutical companies. In addition, Addex

recently received a grant from the Michael J. Fox Foundation to support Phase II clinical testing

of its lead product for Parkinson’s disease. Based upon its technology, which facilitates drug

discovery for challenging therapeutic targets, Addex is developing products that may address

some of the most important diseases such as Alzheimer’s, multiple sclerosis, type II diabetes,

rheumatoid arthritis, depression and sleep disorders.
Tom Saylor, Chair of Eu
ropaBio’s SME Platform
added: “The applicants for this award have

demonstrated how innovation is determined not only by technology, but also by developing

sustainable business models which maximise the use of available funds and design products and

services that bring life-enhancing changes for patients, consumers and the environment as a

whole. At EuropaBio we will continue to help work towards removing
bottlenecks for biotech

SMEs
– like expensive patenting, market fragmentation and slow standard setting– to help these

vital innovators get their ideas to market responsibly and quickly.”
The winners were congratulated by
President Barroso
via a video message and the award was

presented by
Paola Testori Coggi, Director General of DG Health and Consumer Policy
.

Receiving the award on behalf of Addex together with a prize of €10,000 and two years free

membership of EuropaBio,
Chris Maggos, Member of the Executive Management of Addex

Pharmaceuticals
, said “Addex is honoured to receive the recognition of EuropaBio and to be

selected from amongst such an outstanding group of SMEs in this field.” Reacting to the news,

Addex’s CEO Vincent Mutel added: “We look forward to bringing allosteric modulators to

patients as medical therapies, starting with our lead products for Parkinson’s disease and

schizophrenia which will enter phase II clinical trial testing in the next few weeks. Our early

stage products include drugs for Alzheimer’s disease, diabetes and arthritis, all potentially

important therapies for our aging population.”
Commenting on the competition as a whole,
Dr Paul Rübig, MEP
and President of SME Global

who made up part of the judging panel for the award said “The overall quality and level of

innovation demonstrated by the applicants was outstanding. There were many entries

developing beneficial products for patients, consumers and the environment and selecting only

one as a winner was a hard task. I wholeheartedly congratulate Addex on their achievement in

not only pioneering innovation in their field but for doing so in a challenging regulatory and

economic climate for SMEs”.
ENDS.
For further information
on the award or on The Role of Biotechnology in Europe’s Responsible Innovation Event please contact:
Nathalie Moll
Secretary General, EuropaBio
Tel: +32 2 739 11 71; Email:

n.moll@europabio.org

Joanna Dupont Inglis
Communications Manager, EuropaBio
Tel: +32 2 739 11 84; GSM: +32 476 60 71 35 Email:

j.dupont@europabio.org
EuropaBio
is the European Association for Bioindustries, bringing together bioscience companies from all fields of research and

development, testing, manufacturing and distribution of biotechnology products. It has 66 corporate and 7 associated members, 4

BioRegions and 22 National Biotechnology Associations representing some 1800 small and medium sized enterprises.
www.europabio.org